- Home
- GRCE vs VCIG Comparison
GRCE vs VCIG Comparison
Compare GRCE & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- VCIG
- Stock Information
- Founded
- GRCE 2002
- VCIG 2013
- Country
- GRCE United States
- VCIG Malaysia
- Employees
- GRCE N/A
- VCIG N/A
- Industry
- GRCE
- VCIG Diversified Commercial Services
- Sector
- GRCE
- VCIG Consumer Discretionary
- Exchange
- GRCE NYSE
- VCIG Nasdaq
- Market Cap
- GRCE 32.1M
- VCIG 26.3M
- IPO Year
- GRCE N/A
- VCIG 2023
- Fundamental
- Price
- GRCE $2.31
- VCIG $0.32
- Analyst Decision
- GRCE Strong Buy
- VCIG
- Analyst Count
- GRCE 1
- VCIG 0
- Target Price
- GRCE $12.00
- VCIG N/A
- AVG Volume (30 Days)
- GRCE 27.2K
- VCIG 2.7M
- Earning Date
- GRCE 05-15-2025
- VCIG 04-08-2025
- Dividend Yield
- GRCE N/A
- VCIG 155.11%
- EPS Growth
- GRCE N/A
- VCIG N/A
- EPS
- GRCE N/A
- VCIG 7.82
- Revenue
- GRCE N/A
- VCIG $23,548,256.00
- Revenue This Year
- GRCE N/A
- VCIG N/A
- Revenue Next Year
- GRCE N/A
- VCIG N/A
- P/E Ratio
- GRCE N/A
- VCIG $0.04
- Revenue Growth
- GRCE N/A
- VCIG 89.38
- 52 Week Low
- GRCE $2.07
- VCIG $0.29
- 52 Week High
- GRCE $4.97
- VCIG $68.60
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- VCIG 26.92
- Support Level
- GRCE N/A
- VCIG $0.29
- Resistance Level
- GRCE N/A
- VCIG $0.50
- Average True Range (ATR)
- GRCE 0.00
- VCIG 0.12
- MACD
- GRCE 0.00
- VCIG -0.02
- Stochastic Oscillator
- GRCE 0.00
- VCIG 4.31
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development solution consultancy. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology Consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment which focuses on listing solutions, investor relations, and boardroom strategies consultancy. It has established a diverse local and international clientele, providing them with its services in both local and cross-border listings. Its role begins with pre-listing diagnosis and planning to the finalization of the entire listing process.